释放潜力:大麻素 (CBD) 是一个有前途的抗瘤剂
Shuqin Duan1, Mingyu Liu1, Zhechao An1
1State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Heilongjiang, 150081, China.
概括
大麻素 (CBD) 通过抑制癌症生长和转移,显示出显著的抗瘤潜力. 需要进一步的临床试验来确认其有效性,并优化瘤学应用的交付.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 大麻素研究 研究 大麻素研究
背景情况:
- 大麻素 (CBD) 是一种非精神活性大麻化合物,具有已知的抗,止痛和抗炎作用.
- 新兴研究表明,CBD是一种潜在的抗瘤剂,但临床应用受到不一致的临床前数据和不清楚的机制的阻碍.
研究的目的:
- 系统地审查CBD在各种癌症类型中的抗瘤疗效.
- 阐明CBD在瘤学中的作用机制,安全概况和治疗潜力.
- 讨论CBD在癌症治疗中的挑战和未来方向.
主要方法:
- 系统性审查整合了最近关于CBD抗癌作用的高质量研究.
- 分析CBD对瘤细胞生物学和瘤微环境 (TME) 的影响.
- 评估单疗法与组合疗法,症状管理和药物动力学,包括基于纳米的输送系统.
主要成果:
- CBD表现出多目标的抗瘤活性,抑制增殖,诱导亡,并抑制转移.
- 在体外和体内已证明广泛的疗效,在组合疗法中具有协同效应.
- 观察到有利的安全性和耐受性概况,具有治疗癌症相关症状的潜力;然而,证据主要是临床前的.
结论:
- 作为一种抗瘤剂,CBD显示出相当大的希望,为合理的药物开发提供了基础.
- 进一步的研究至关重要,重点是临床验证,优化药物输送系统和标准化治疗方案.
- 将临床前发现转化为有效的临床瘤学策略需要严格的调查.
相关概念视频
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
665
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
665
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K